10x Genomics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
10x Genomics (TXG) has risen 84% in 3 months, driven by consumables growth and Atera demand. Q2 2026 consumables revenue increased 7% YoY, with Single Cell up 3% and Spatial up 16%. Management raised 2026 revenue guidance to $610M-$630M. However, instrument sales fell 47.2% YoY, and the company reported a $19.6M operating loss. TXG trades at 11.9X forward sales, a premium to peers.
10x Genomics (TXG) won a patent infringement case against Parse Biosciences, a Qiagen (QGEN) subsidiary, with a jury awarding $4.8M in damages. The ruling strengthens TXG's IP in single-cell analysis. Despite the win, TXG shares fell 5%. The company seeks enhanced damages and a permanent injunction in post-trial proceedings.
Saxonov Serge (Chief Executive Officer) sold 10,486 shares of 10x Genomics, Inc. (TXG) at an average of $63.69 ($63.02–$64.75, $0.67M total) across 3 trades on 2026-08-26 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 2 news stories mentioning TXG (10x Genomics, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent TXG coverage spans financial news, insider activity and earnings.
In the last 30 days, TXG insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($5.5M). The most active reporter was Saxonov Serge, Chief Executive Officer, with 4 filings. 58% of those filings were made under pre-arranged Rule 10b5-1 plans.
Guidance raise suggests higher near-term revenue, supporting the recent 84% rally but valuation remains premium.
Despite the favorable verdict, TXG shares fell >5% on the news.
Insider sale of ~0.6% of holdings may signal short‑term bearish pressure.
The award provides a modest cash inflow and may improve short‑term sentiment.
Positive legal outcome for 10x Genomics may boost short‑term sentiment.
alphai scores every news story that mentions TXG with an AI model for sentiment and relevance, and aggregates insider trades from 10x Genomics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
10x Genomics (TXG) has risen 84% in 3 months, driven by consumables growth and Atera demand. Q2 2026 consumables revenue increased 7% YoY, with Single Cell up 3% and Spatial up 16%. Management raised 2026 revenue guidance to $610M-$630M. However, instrument sales fell 47.2% YoY, and the company reported a $19.6M operating loss. TXG trades at 11.9X forward sales, a premium to peers.
3 min read10x Genomics (TXG) won a patent infringement case against Parse Biosciences, a Qiagen (QGEN) subsidiary, with a jury awarding $4.8M in damages. The ruling strengthens TXG's IP in single-cell analysis. Despite the win, TXG shares fell 5%. The company seeks enhanced damages and a permanent injunction in post-trial proceedings.
2 min readSaxonov Serge (Chief Executive Officer) sold 10,486 shares of 10x Genomics, Inc. (TXG) at an average of $63.69 ($63.02–$64.75, $0.67M total) across 3 trades on 2026-08-26 under a Rule 10b5-1 trading plan.
1 min read10x Genomics won a $4.8 million award in a patent case against a Qiagen unit. The ruling may impact both companies' financials and legal strategies.
1 min readA jury ruled that Parse Biosciences, now part of Qiagen, willfully infringed three patents licensed to 10x Genomics. The patents were found valid, and 10x was awarded $4.8M in damages. 10x seeks further damages and an injunction. The case involved patents for single-cell analysis technology.
2 min readSaxonov Serge (Chief Executive Officer) sold 18,545 shares of 10x Genomics, Inc. (TXG) at $63.02 ($1.17M total) on 2026-08-24.
1 min readTaich Adam (Chief Financial Officer) sold 17,166 shares of 10x Genomics, Inc. (TXG) at $63.02 ($1.08M total) on 2026-08-24.
1 min readHindson Benjamin J. (See Remarks) sold 13,818 shares of 10x Genomics, Inc. (TXG) at $63.02 ($0.87M total) on 2026-08-24.
1 min read10x Genomics (TXG) officer Adam Taich plans to sell 16,614 shares, valued at $1,081,903.68, under Rule 144. The shares are part of a 32,650-share Restricted Stock Unit Grant acquired on August 21, 2026. The sale is expected to occur on August 24, 2026, through Morgan Stanley Smith Barney LLC Executive Services.
1 min read10x Genomics (TXG) insider Serge Saxonov plans to sell 17,948 shares, valued at $1.17M, through Morgan Stanley. The shares were acquired via a Restricted Stock Unit Grant. TXG has 120.2M shares outstanding. Prior sales by Saxonov were also disclosed.
1 min read
